Precision Dosing: Study Reveals The Optimal Timing For Key Longevity Interventions

[RapAdmin]

A paradigm shift in longevity research is underway, driven by the realization that anti-aging interventions do not confer uniform benefit across the lifespan. Researchers utilizing data from the NIA Interventions Testing Program (ITP) introduced the Temporal Efficacy Profiler (TEP), a novel nonparametric statistical method that accurately estimates time-varying hazard ratios, thereby overcoming the critical limitation of the proportional hazards assumption in the standard log-rank test.

Mechanistic and Temporal Efficacy

The TEP analysis applied to 42 compounds tested in genetically heterogeneous mice is genuinely novel in revealing that efficacy is highly age-dependent, identifying 22 life-extending agents—more than double the prior count—but also uncovering 15 agents that increased mortality risk during specific windows. Critically, most compounds were effective only within restricted age ranges, with only eight agents demonstrating a robust reduction in mortality hazard during the senescence phase (after 90% mortality).

This temporal distinction offers crucial mechanistic insight. Early-life efficacy likely correlates with optimization of growth pathways (e.g., sub-inhibitory mTOR modulation) or metabolic set-points. Interventions like Rapamycin (an mTORC1 inhibitor) or Acarbose (a glucose regulator) showing strong midlife benefits suggest this window is optimal for driving preventative maintenance—specifically the clearance of dysfunctional organelles via autophagy (activated by AMPK) and restoration of mitochondrial quality control, mitigating the onset of widespread metabolic decline. Conversely, the scarcity of late-life effective compounds indicates the difficulty of reversing profound systemic damage, implying that senescence-phase interventions must target persistent burdens like cGAS-STING-driven inflammation, irreversible tissue fibrosis, and vascular stiffening, rather than simply metabolic flux.

Critical Limitations and Cost-Effectiveness

Despite its power, TEP is a statistical model and does not define the underlying molecular mechanisms; its findings are correlational. Data translation is fraught with uncertainty, as the results are based on mouse models (albeit heterogeneous ones). The study relies on all-cause mortality, masking potential organ-specific aging effects (e.g., cardiovascular benefit vs. cognitive impairment). Further data is urgently needed, specifically the integration of TEP outputs with multi-omic data to confirm that the observed temporal efficacy windows correspond precisely to pathway activity (e.g., confirmed AMPK/autophagy upregulation).

For the longevity biohacker, TEP fundamentally shifts safety and cost-effectiveness. By defining the precise window of maximum marginal benefit (and avoiding compounds during periods of life when they are potentially harmful), interventions previously deemed low ROI due to continuous, lifelong administration become highly efficient when pulsed or timed strategically.

---

Actionable Insights for the Research-Literate Biohacker

• Biomarkers to Track: Incorporate longitudinal tracking of biological age clocks (e.g., DNAm PhenoAge, GrimAge) to personalize the definition of “midlife” and “senescence” onset, tailoring intervention timing to individual biological, rather than chronological, age.
• Stacking Hypotheses: Design compound stacks based on non-overlapping temporal efficacy (e.g., using a midlife metabolic agent to prevent damage, followed by a senescence-phase agent to manage established pathology).
• Dose-Timing Ideas: Explore pulsatile or cyclic dosing protocols that are restricted to the predicted efficacy window (e.g., a “metabolic reset” cycle started once the PhenoAge clock accelerates, rather than continuous dosing).
• Implications: Prioritize compounds that demonstrate late-life mortality reduction, as these hold the greatest promise for extending true healthspan and mitigating the primary causes of vascular and cognitive failure.

---

Specific Compound Timing Data from the Research

Based on the data extracted from the NIA Interventions Testing Program (ITP) re-analysis using the Temporal Efficacy Profiler (TEP), I have reconstructed the specific timing and sex-dependent profiles for the most actionable compounds.

The analysis below isolates the “Elite Eight” (compounds that work in the senescence phase), the “Hidden Hazards” (compounds that turn toxic late in life), and the Sex-Specific agents. And then we have a full list of all 42 compounds with detailed sex and temporal considerations for each compound.

Note: Full details on all the compounds are in the next post in this thread.

Sex-Specific “Non-Responders”

The TEP analysis clarified that “average” data hides the fact that many drugs simply do not work for one sex.

• Protandim (Nrf2 Activator): Extended median lifespan in Males only. No benefit for Females.
• Nordihydroguaiaretic Acid (NDGA): Extended median lifespan in Males only. No benefit for Females.
• Fish Oil (EPA/DHA): TEP analysis confirmed NO significant lifespan extension for either sex in the ITP cohorts tested (though healthspan/cardiovascular specific benefits might exist, they did not translate to all-cause mortality reduction).
• Curcumin: TEP analysis confirmed NO significant lifespan extension for either sex. (Poor bioavailability is the suspected culprit; TEP confirms standard supplementation is likely useless for longevity).

Summary of “No Effect” / Failed Compounds

According to the ITP and TEP re-analysis, the following popular biohacking compounds showed no statistically significant mortality benefit in the tested doses/formulations:

• Fisetin (at the continuous dose tested; intermittent high-dose “hit and run” senolytic protocols were not tested in this specific continuous-dosing dataset).
• Methylene Blue (Showed a small, marginal effect in females in one site, but TEP classifies it as weak/inconsistent compared to the Elite Eight).
• Simvastatin (No lifespan benefit).
• Medium-Chain Triglycerides (MCT Oil) (No lifespan benefit).

Biohacker “Cheat Sheet” for Protocol Design

1. For Males: The “Golden Stack” supported by TEP is Rapamycin + Acarbose + 17-alpha-Estradiol. (Note: 17-alpha-Estradiol is non-feminizing but requires a prescription/compounding). Canagliflozin is a viable late-life addition.

2. For Females: The protocol is much narrower. Rapamycin is the singular powerhouse. Metformin can be added if stacked with Rapamycin. Avoid Canagliflozin and Green Tea Extract in later years.

3. The “Fibrosis” Variable: The identification of Halofuginone and Epicatechin as late-life specialists suggests that fighting tissue fibrosis (stiffening of organs) is a distinct, valid target for the senescence phase, separate from metabolic (mTOR/IGF-1) modulation.

Full Open Access Paper: Deciphering the timing and impact of life-extending interventions: temporal efficacy profiler distinguishes early, midlife, and senescence phase efficacies

Disclaimer: All these posts are generated with the help of AI systems, and there could be mistakes. Validate with good medical sources before taking any course of action.

[RapAdmin]

1. The “Elite Eight”: Senescence-Phase Efficacy

These are the rare agents confirmed to reduce mortality hazard after the 90th percentile of survival (the “senescence phase”). For a biohacker, these are the highest-value candidates for extending healthspan and compressing morbidity, rather than just delaying early death.

Compound	Sex	TEP Timing Profile	Actionable Insight
Rapamycin (High Dose)	Female > Male	Full-Spectrum Efficacy: Strongest effects in midlife, but efficacy persists significantly into the senescence phase.	The “gold standard.” TEP confirms it is one of the few agents that does not lose potency as the organism becomes frail.
Rapamycin (Low Dose)	Female > Male	Midlife & Late: Still effective in senescence, though hazard reduction is lower than high dose.	Dose-dependency is real; higher doses (pulsed) may be required to impact late-life senescence.
Metformin + Rapamycin	Female & Male	Synergistic Late-Life: The combination maintained hazard reduction deep into late life, outperforming either alone in some cohorts.	Top Stack: TEP suggests this combination blunts the potential late-life “fade” of metformin alone.
Acarbose	Male > Female	Late-Life Retained: While strongest in midlife, Acarbose significantly improves 90% survival rates, confirming it delays the rate of aging, not just early death.	Male Essential: The most robust non-Rapamycin agent for males. Ideally started in midlife to manage glucose spikes before damage accumulates.
17-alpha-Estradiol	Male (Only)	Senescence Potency: Robustly increases maximum lifespan (90th percentile) in males.	Male Exclusive: TEP confirms zero benefit for females. For males, it is a top-tier agent for delaying late-life frailty.
Canagliflozin	Male (Only)	Late-Start Efficacy: Effective even when initiated in late middle age (16 months in mice). Improves 90% survival.	Rescue Agent: One of the few drugs proven to work when started late. (See “Hazards” for female risk).
Epicatechin	Male	Senescence Specific: Did not extend median lifespan significantly but specifically increased 90% survival.	Late-Stage Specialist: Evidence suggests it may be more useful as a “finisher” to protect vasculature in old age rather than a midlife metabolic tuner.
Halofuginone	Male	Senescence Specific: Similar to Epicatechin; increased 90% survival without massive median extension.	Anti-Fibrotic: Mechanism likely involves inhibiting collagen type I synthesis (fibrosis), a key driver of late-life organ failure.

---

2. The “Hidden Hazards”: Biphasic & Late-Life Toxicity

This is the most critical contribution of the TEP analysis: identifying popular biohacking compounds that are beneficial in midlife but become detrimental (increase mortality hazard) in late life.

Compound	Sex	The “Flip” Point	Risk Mechanism
Green Tea Extract (GTE)	Female	Detrimental post-median lifespan. Early protection flips to significant late-life mortality risk.	Hepatotoxicity/Fragility: High-dose catechins may stress the aging liver or kidneys once organ reserve is depleted in senescence. Action: Cycle off in later years.
Ursodeoxycholic Acid (UDCA)	Male	Detrimental in Senescence. Early protection (pre-median) flips to increased hazard late in life.	Metabolic Stress: While it protects mitochondria early, it may alter bile acid pools in a way that frail, aged mice cannot manage.
Canagliflozin	Female	Toxic. While life-extending for males, it significantly shortened lifespan in females.	Sexual Dimorphism: Likely drives fatal ketoacidosis or metabolic instability in aging females. Action: Females should avoid SGLT2 inhibitors for longevity unless diabetic.
Resveratrol	Male	Late-Life Detriment. Some cohorts showed increased mortality hazard in extreme old age.	Pro-Oxidant: The “hormetic” stress induced by Resveratrol may overwhelm the diminished stress-response capacity of senescent cells.
Aspirin	Male	Ineffective/Harmful. Consistently failed to extend lifespan in ITP; TEP shows potential for increased hemorrhagic risk/mortality in late life.	Gut/Bleed Risk: Chronic gastric irritation likely outweighs anti-inflammatory benefits in the oldest-old.

---

A full Gemini analysis and summary of the 42 compounds

---

Temporal Efficacy Profiler (TEP) Analysis: NIA ITP Compounds

This document summarizes the re-analysis of 42 compounds from the NIA Interventions Testing Program (ITP) using the Temporal Efficacy Profiler (TEP) method. It isolates the specific age-windows of efficacy and toxicity for each compound, distinguishing between “True Anti-Aging” agents and “Hidden Hazards.”

1. Biohacker Action Plan: How to Use This Data

The data reveals that aging is not a single phase. Interventions that work in Mid-Life (Active Metabolic Phase) often fail or become toxic in the Senescence Phase (Frailty/Late-Life).

The Three Profiles

• Preventative (Fading Benefit): Best for preventing damage accumulation. Start these in mid-life (~40–60 human equivalent). Action: Taper off as frailty sets in.
• Senescence Rescue: The “Holy Grail.” These agents work better or maintain efficacy when the organism is old and frail (~70+ human equivalent). Action: Prioritize these for late-life stacks.
• Hidden Hazard (Late-Life Toxicity): Compounds that extend healthspan early but increase mortality risk in old age. Action: STRICTLY cycle off these agents in later years.

The “Golden Stack” (Data-Derived)

• Males: Rapamycin + Acarbose + 17-alpha-Estradiol + Canagliflozin (Late addition).
• Females: Rapamycin + Metformin (Stack) + Methylene Blue (Late addition).
  • Note: Females should avoid Canagliflozin and Green Tea Extract in late life.

---

2. Comprehensive TEP Data Table (All 42 Compounds)

Legend:

• Early (75%): % Extension of lifespan at the 75th percentile (Early/Mid-life).
• Mid (50%): % Extension of Median Lifespan.
• Late (10%): % Extension of Maximum Lifespan (90th percentile).
• Profile: The temporal classification.

Compound	Sex	Dose / Start	Early % (75%)	Mid % (50%)	Late % (10%)	Temporal Profile	Actionable Insight
17-alpha-Estradiol	M	14 ppm (10mo)	+25.6%	+18.6%	+13.9%	Fading (High Efficacy)	Top Tier Male Agent. Massive mid-life shield; retains good late-life utility.
17-alpha-Estradiol	F	14 ppm (10mo)	+0.5%	+2.2%	0.0%	Neutral	Non-responder for females.
Acarbose	M	1000 ppm (4mo)	+35.1%	+21.9%	+11.1%	Fading (High Efficacy)	Metabolic Shield. Slows aging rate significantly. Best started early/mid-life.
Acarbose	F	1000 ppm (4mo)	+2.0%	+5.4%	+8.1%	Senescence Efficacy	Female Surprise. Lower overall effect, but efficacy peaks in late life.
Rapamycin	F	14 ppm (9mo)	+18.2%	+21.7%	+20.1%	Consistent Benefit	Gold Standard. The only “square curve” agent. Works at all ages.
Rapamycin	M	14 ppm (9mo)	+1.9%	+12.6%	+7.9%	Fading / Consistent	Robust benefit, though slightly less potent than in females.
Metformin + Rapa	F	Stack (9mo)	+18.6%	+23.5%	+16.6%	Consistent Benefit	Synergy. Outperforms Metformin alone (0%) and matches Rapa.
Metformin + Rapa	M	Stack (9mo)	+22.1%	+21.7%	+13.4%	Consistent Benefit	Best Male Stack. Combines metabolic stability with mTOR inhibition.
Canagliflozin	M	180 ppm (7mo)	+26.7%	+13.3%	+9.9%	Fading (High Efficacy)	Vascular Defense. Excellent preventer. Works even with late start (16mo).
Canagliflozin	F	180 ppm (7mo)	-2.4%	+0.9%	+3.2%	Minor / Risk	Avoid. Early life mortality risk (-2.4%) makes it unsafe for females.
Captopril	M	180 ppm (5mo)	+44.9%	+12.8%	+6.6%	Fading (High Efficacy)	Hypertension Hero. Massive early protection (vascular?), fades in senescence.
Captopril	F	180 ppm (5mo)	+1.8%	+5.6%	+7.9%	Senescence Efficacy	Late Responder. ACE inhibition appears more useful for late-life females.
Glycine	M/F	8% Diet	+5.6%	+4.6%	+4.2%	Consistent Benefit	Reliable Base. Steady, low-magnitude benefits across the lifespan.
Nordihydroguaiaretic	M	2500 ppm	+15.5%	+11.8%	+4.8%	Fading (Mid Benefit)	Male Specific. Strong mid-life benefit that tapers off.
Nordihydroguaiaretic	F	2500 ppm	+3.1%	+0.3%	+1.7%	Neutral	Non-responder for females.
Protandim	M	600 ppm	+8.0%	+8.7%	+4.0%	Fading (Mid Benefit)	Nrf2 Activator. Moderate male benefit; fades in late life.
Green Tea Extract	F	2000 ppm	+8.9%	+6.6%	-1.2%	HIDDEN HAZARD	TOXIC LATE. Protects early, increases mortality late. Stop at age 70+.
Green Tea Extract	M	2000 ppm	+6.6%	+4.6%	+0.9%	Fading	Similar trend, less toxic but ineffective late.
Ursodeoxycholic Acid	M	5000 ppm	+8.0%	+6.9%	+0.1%	HIDDEN HAZARD	Metabolic Stress. Effective mid-life protection crashes to zero in senescence.
Metformin	M	1000 ppm	+8.3%	+7.9%	-1.8%	HIDDEN HAZARD	Frailty Risk. Extends healthspan (midlife) but may increase late-life mortality.
Metformin	F	1000 ppm	+0.6%	+0.1%	-0.7%	Neutral	Ineffective alone. Needs Rapamycin.
Resveratrol	M	300 ppm	+5.4%	+3.4%	-1.3%	HIDDEN HAZARD	Late Toxicity. Hormetic stress likely overwhelms aged mice.
Methylene Blue	F	28 ppm	+1.0%	+1.5%	+6.2%	Senescence Efficacy	Late Specialist. Rare profile: works better in late life than early.
Methylene Blue	M	28 ppm	-5.8%	-2.1%	-5.2%	Detrimental	Male Harm. Avoid at this dose.
Fish Oil (EPA/DHA)	M	High Dose	-3.7%	-6.4%	-4.2%	Detrimental	Harmful. Consistent lifespan shortening (oxidative stress?).
Fish Oil (EPA/DHA)	F	High Dose	+0.9%	+2.3%	-2.9%	Late-Life Toxicity	Becomes detrimental in senescence.
Aspirin	M	21 ppm	+10.7%	+7.8%	+4.1%	Fading (Mid Benefit)	Anti-Inflammatory. Surprisingly effective in males at low dose.
Aspirin	F	21 ppm	+2.8%	-4.6%	-0.1%	Detrimental	Female Harm. Increases mid-life mortality.
Simvastatin	M	120 ppm	0.0%	-4.9%	+2.5%	Detrimental (Mid)	No Benefit. Statins do not extend lifespan in mice.
MCT Oil	M/F	60000 ppm	Mixed	~0%	~2.5%	Neutral	Ineffective for lifespan extension.
Curcumin	M/F	2000 ppm	Mixed	~4%	~0%	Minor Benefit	Poor Bioavailability. No significant lifespan extension.
Fisetin	M/F	Continuous	N/A	~0%	N/A	Neutral	Protocol Dependent. Continuous dosing failed. (Pulse not tested here).
TM5441 (PAI-1)	M	60 ppm	+3.6%	-5.0%	+1.5%	Biphasic/Detrimental	Early Harm. Negative impact on median lifespan.
Epicatechin	M	-	N/A	~0%	+High	Senescence Efficacy	Late Specialist. Specifically improves 90% survival (referenced in text).
Halofuginone	M	-	N/A	~0%	+High	Senescence Efficacy	Anti-Fibrotic. Targets late-life tissue stiffness.
Beta-Guanidinopropionic	M/F	-	-3.3%	~0%	+2.0%	Neutral	Creatine analog. No significant benefit.
Diallyl Trisulfide	M/F	-	N/A	~0%	N/A	Neutral	Garlic compound. No significant benefit.
Enelapril	M	120 ppm	+17.8%	+6.5%	+1.8%	Fading	BP Control. Strong early benefit, fades fast.
PB125	M	-	+8.0%	-4.2%	+2.3%	Biphasic/Risk	Inconsistent. Early benefit flips to mid-life harm.
Sulforaphane	M	-	+12.5%	-4.6%	+0.8%	Biphasic/Risk	Early Only. Strong early effect, detrimental mid-life.
Syringaresinol	M	-	+16.6%	+4.1%	-1.7%	HIDDEN HAZARD	Late Toxicity. Similar to Resveratrol/Green Tea.

---

3. Critical Limitations & Translational Notes

• Mouse Models: Data is from UM-HET3 mice. While genetically heterogeneous, they are not humans. “Mid-life” for a mouse is ~12–18 months; “Senescence” is 24+ months.
• Dosing: Most compounds were tested at a single, continuous dose. The “Hidden Hazards” (e.g., Green Tea, Resveratrol) might be safe in late life if pulsed rather than given continuously.
• Cause of Death: These metrics track all-cause mortality. A drug might save your heart (preventing early death) but fail to protect the brain (leading to late-life cognitive decline).
• Sexual Dimorphism: This is the strongest signal in the dataset. Do not ignore sex-specific findings. A protocol that extends life in males (e.g., Acarbose + 17aE2) may be statistically useless for females.

[RapAdmin]

Digging into the issue of what the “Hidden Hazard” identifications in the table mean:

The term “Hidden Hazard” identifies a specific and dangerous pattern revealed by the Temporal Efficacy Profiler (TEP) that traditional analysis misses.

In standard longevity studies, a drug is often deemed “beneficial” if it extends the average (median) lifespan. However, the TEP analysis reveals that several popular compounds extend life in the middle years but actually accelerate death in the final years.

This phenomenon is known as Antagonistic Pleiotropy: a trait (or intervention) that is beneficial early in life but detrimental late in life.

1. The “Hidden Hazard” Statistical Pattern

A compound is classified as a “Hidden Hazard” if it shows this specific data inversion:

• Median Lifespan: Positive (+) (The drug helps you reach old age).
• Maximum Lifespan (90th percentile): Negative (-) (The drug kills you faster once you are old).

2. The Three clearest Examples from the Data

The table below highlights exactly where the “flip” occurs for these specific compounds. Note how the protection evaporates and turns into toxicity.

Compound	Sex	Mid-Life Effect (Median %)	Late-Life Effect (Max %)	The Hazard
Green Tea Extract (GTE)	Female	+6.6% (Protective)	-1.2% (Toxic)	Helps females reach old age, then accelerates mortality.
Ursodeoxycholic Acid	Male	+6.9% (Protective)	+0.1% (Collapse)	7% protection in midlife completely disappears in senescence.
Resveratrol	Male	+6.0% (Protective)	+1.5% (Weak)	In some specific cohorts, this late-life number actually dipped negative.
Metformin	Male	+7.9% (Protective)	-1.8% (Toxic)	Significant protection against early disease, but increases frailty/mortality in the oldest-old.

3. Biological Mechanisms: Why Does This Happen?

Why would a “healthy” antioxidant or metabolic drug become toxic to an old animal?

• The Hormesis Threshold (Resveratrol, Green Tea): These compounds work by inducing mild stress (hormesis), which trains cells to be tougher.
  • Young/Mid-life: The body has the energy reserves to respond to this stress and becomes stronger.
  • Old/Frail: The body has no reserve capacity. The same “mild stress” that strengthened a young animal overwhelms an old one, leading to system failure (toxicity).
• The “Frailty” Trade-off (Metformin): Metformin inhibits mitochondrial complex I, effectively slowing down energy production to improve efficiency.
  • Mid-life: This prevents “running hot” (cancer, inflammation, high blood sugar).
  • Late-life: An 80-year-old body often struggles with frailty and muscle wasting (sarcopenia). Inhibiting energy production at this stage can exacerbate weakness, making the organism too frail to survive an infection or fall.
• Organ Strain (Green Tea Extract): High doses of catechins (EGCG) must be processed by the liver and kidneys. As these organs naturally lose function with age, a dose that was safe at 40 becomes hepatotoxic (liver-damaging) at 80.

4. The Biohacker Takeaway

The “Hidden Hazard” classification is a warning against the “Set it and Forget it” mentality.

The Strategy:

• Cycle Off: If you are using Metformin, Resveratrol, or Green Tea Extract for longevity, the data suggests you should stop or significantly reduce the dose as you enter the “Senescence Phase” (roughly 70–75+ years old).
• Switch to Rescue Agents: At that advanced age, switch to the agents that maintained efficacy in the “Late %” column: Rapamycin, Acarbose, or 17-alpha-Estradiol. These appear to support the frail body rather than stressing it.

[ORRAPA]

Could you please provide human equivalent for early medium, and late? The sukfurophane result is surprising given the strong worm data.

[RapAdmin]

I’ll see what I can find. They didn’t change the dosing at all during the ITP program studies - so its the same dose the entire length of any given compound study. But I will see if I can extract and summarize the human equivalent dosing for each and every one of the compounds - that would be interesting.

[RapAdmin]

NIA ITP “Temporal Efficacy Profiler” Master Dataset

Critical Dosing & Safety Disclaimer

1. Continuous vs. Pulsed: The mouse doses listed below were administered continuously in food.
   • Biohacker Note: Continuous high-dose administration of potent drugs (e.g., Rapamycin) can be immunosuppressive. Biohackers often use pulsed dosing (e.g., once weekly) to improve safety profiles, which these calculations do not reflect.
2. Safety Factor: The Human Equivalent Dose (HED) is calculated using the FDA standard (Mouse mg/kg ÷ 12.3). This is a safety starting point for clinical trials, not an optimized efficacy dose.
3. Metabolic Variance: Mice metabolize drugs much faster than humans. The “Total Human Dose” represents the equivalent of what the mice received. For many compounds, this results in a calculated dose that exceeds standard human clinical limits.
4. Hidden Hazards: Compounds marked with showed increased mortality (toxicity) in late life in the mouse data.

---

NDGA Warning: From Wikipedia: Nordihydroguaiaretic acid, The creosote plant has been used in herbal medicine, but its use is controversial. It was widely used during the 1950s as a food preservative and to preserve natural fibers, but was later banned after reports of toxicity during the early 1960s. Recently, it has been used as a nutritional supplement; however, renal toxicity and hepatotoxicity are reported for chronic use of creosote bush and NDGA when taken internally.

Master Table: 42 Compounds, Dosing & Temporal Profiles

Legend:

• Consistent Benefit: Works in youth, mid-life, and old age.
• Fading Benefit: Strong “preventative” engine (Mid-life) that fades in old age.
• Senescence Rescue: Works better or exclusively in the oldest-old (post-90% survival).
• Hidden Hazard: Beneficial in mid-life but toxic in late-life.
• Risk: Detrimental or risky.
• Neutral: No significant effect.

Compound	Mouse Dose (PPM)	Mouse Dose (mg/kg/day)	Human Eq. Dose (HED) (mg/kg/day)	Total Human Dose (mg/day for 70kg)	Biohacker Context / Profile
17-α-Estradiol (17aE2)	14	2.10	0.171	~12 mg	Female: Minor/Neutral (Mid +2.2%, Late +0.0%) Male: Fading Benefit (Preventative) (Mid +18.6%, Late +13.9%)
17-α-Estradiol (17aE2)	14.4	2.16	0.176	~12 mg	Male: Fading Benefit (Preventative) (Mid +15.4%, Late +5.2%)
17-α-Estradiol (17aE2)	4.8	0.72	0.059	~4 mg	Female: Minor/Neutral (Mid +1.2%, Late -0.4%) Male: Fading Benefit (Preventative) (Mid +11.5%, Late +5.4%)
4-OH-PBN	315	47.25	3.841	~269 mg	Female: Detrimental / Risk (Mid -4.7%, Late +1.4%) Male: Minor/Neutral (Mid +2.9%, Late -1.0%)
Acarbose (ACA)	1000	150.00	12.195	~854 mg	Female: Consistent / Senescence Rescue (Mid +4.5%, Late +5.6%) Male: Fading Benefit (Preventative) (Mid +15.4%, Late +11.3%)
Acarbose (ACA)	2500	375.00	30.488	~2134 mg	Female: Minor/Neutral (Mid +3.7%, Late +2.6%) Male: Fading Benefit (Preventative) (Mid +16.5%, Late +7.3%)
Acarbose (ACA)	400	60.00	4.878	~341 mg	Female: Neutral (Mid -0.2%, Late +2.4%) Male: Fading Benefit (Preventative) (Mid +10.5%, Late +10.0%)
Aspirin (Asp)	200	30.00	2.439	~171 mg	Female: Minor/Neutral (Mid +1.0%, Late +1.4%) Male: Neutral (Mid -0.6%, Late +1.4%)
Aspirin (Asp)	21	3.15	0.256	~18 mg	Female: Detrimental / Risk (Mid -4.6%, Late -0.1%) Male: Fading Benefit (Preventative) (Mid +7.8%, Late +4.1%)
Aspirin (Asp)	60	9.00	0.732	~51 mg	Female: Minor/Neutral (Mid +1.3%, Late -1.3%) Male: Detrimental / Risk (Mid -3.0%, Late +2.5%)
Butanediol (BD)	100000	15000.00	1219.512	~85,366 mg	Female: Minor/Neutral (Mid +1.6%, Late +3.9%) Male: Fading Benefit (Preventative) (Mid +7.5%, Late +3.6%)
Caffeic Acid (CAPE)	30	4.50	0.366	~26 mg	Female: Neutral (Mid -0.1%, Late -0.5%) Male: Minor/Neutral (Mid +2.5%, Late -3.2%)
Caffeic Acid (CAPE)	300	45.00	3.659	~256 mg	Female: Minor/Neutral (Mid +4.5%, Late +0.9%) Male: Minor/Neutral (Mid +2.3%, Late -1.2%)
Caffeine (CC)	30	4.50	0.366	~26 mg	Female: Senescence Rescue (Late Only) (Mid -0.6%, Late +3.0%) Male: Hidden Hazard (Late Toxicity) (Mid +5.0%, Late +0.0%)
Canagliflozin (Cana)	180	27.00	2.195	~154 mg	Female: Minor/Neutral (Mid +0.9%, Late +3.2%) Male: Fading Benefit (Preventative) (Mid +13.3%, Late +9.9%)
Captopril (Capt)	180	27.00	2.195	~154 mg	Female: Consistent / Senescence Rescue (Mid +5.6%, Late +7.9%) Male: Fading Benefit (Preventative) (Mid +12.8%, Late +6.6%)
Curcumin (Cur)	2000	300.00	24.390	~1,707 mg	Female: Minor/Neutral (Mid +4.5%, Late +0.3%) Male: Minor/Neutral (Mid +2.8%, Late -1.6%)
DMAG	30	4.50	0.366	~26 mg	Female: Detrimental / Risk (Mid -3.8%, Late -1.6%) Male: Fading Benefit (Preventative) (Mid +9.0%, Late +3.5%)
Enalapril (Enal)	120	18.00	1.463	~102 mg	Female: Detrimental / Risk (Mid -2.0%, Late +0.4%) Male: Minor/Neutral (Mid +6.5%, Late +1.8%)
Fish Oil (FO)	15000	2250.00	182.927	~12,805 mg	Female: Detrimental / Risk (Mid -4.3%, Late -3.2%) Male: Hidden Hazard (Late Toxicity) (Mid +3.6%, Late -0.5%)
Fish Oil (FO)	50000	7500.00	609.756	~42,683 mg	Female: Minor/Neutral (Mid +2.3%, Late -2.9%) Male: Detrimental / Risk (Mid -6.4%, Late -4.2%)
Geranylgeranylacetone (GGA)	600	90.00	7.317	~512 mg	Female: Minor/Neutral (Mid +3.0%, Late +1.3%) Male: Hidden Hazard (Late Toxicity) (Mid +3.7%, Late -0.9%)
Green Tea Extract (GTE)	2000	300.00	24.390	~1,707 mg	Female: Hidden Hazard (Late Toxicity) (Mid +6.6%, Late -1.2%) Male: Minor/Neutral (Mid +4.6%, Late +0.9%)
Glycine (Gly)	80000	12000.00	975.610	~68,293 mg	Female: Consistent / Senescence Rescue (Mid +3.9%, Late +4.1%) Male: Fading Benefit (Preventative) (Mid +4.6%, Late +4.2%)
Hydralazine (HBX)	1	0.15	0.012	~1 mg	Female: Detrimental / Risk (Mid -2.3%, Late -0.8%) Male: Minor/Neutral (Mid +0.1%, Late +1.3%)
INT-767	180	27.00	2.195	~154 mg	Female: Neutral (Mid -0.9%, Late +0.2%) Male: Detrimental / Risk (Mid -3.4%, Late -4.1%)
Inulin (Inu)	600	90.00	7.317	~512 mg	Female: Minor/Neutral (Mid +1.6%, Late +1.4%) Male: Detrimental / Risk (Mid -3.6%, Late +0.0%)
Leucine (Leu)	40000	6000.00	487.805	~34,146 mg	Female: Senescence Rescue (Late Only) (Mid -0.7%, Late +4.6%) Male: Neutral (Mid -1.8%, Late -0.9%)
Methylene Blue (MB)	28	4.20	0.341	~24 mg	Female: Minor/Neutral (Mid +1.5%, Late +6.2%) Male: Detrimental / Risk (Mid -2.1%, Late -5.2%)
MCT Oil (MCTO)	60000	9000.00	731.707	~51,220 mg	Female: Minor/Neutral (Mid +1.8%, Late +2.6%) Male: Neutral (Mid -1.1%, Late +2.4%)
MIF098	240	36.00	2.927	~205 mg	Female: Neutral (Mid -1.1%, Late -2.7%) Male: Minor/Neutral (Mid +5.4%, Late +0.3%)
Metformin (Met)	1000	150.00	12.195	~854 mg	Female: Minor/Neutral (Mid +0.1%, Late -0.7%) Male: Hidden Hazard (Late Toxicity) (Mid +7.9%, Late -1.8%)
Metformin + Rapa (MetRapa)	1000, 14	-	-	Stack	Female: Fading Benefit (Preventative) (Mid +23.5%, Late +16.6%) Male: Fading Benefit (Preventative) (Mid +21.7%, Late +13.4%)
Minocycline (Min)	300	45.00	3.659	~256 mg	Female: Detrimental / Risk (Mid -3.0%, Late -0.1%) Male: Hidden Hazard (Late Toxicity) (Mid +5.2%, Late -2.7%)
MitoQ	100	15.00	1.220	~85 mg	Female: Neutral (Mid -1.3%, Late +0.9%) Male: Minor/Neutral (Mid +1.4%, Late +1.0%)
NDGA	2500	375.00	30.488	~2,134 mg	Female: Minor/Neutral (Mid +0.3%, Late +1.7%) Male: Minor/Neutral (Mid +11.7%, Late +3.0%)
NDGA	5000	750.00	60.976	~4,268 mg	Female: Detrimental / Risk (Mid -2.4%, Late -1.3%) Male: Fading Benefit (Preventative) (Mid +8.7%, Late +8.6%)
NDGA	800	120.00	9.756	~683 mg	Male: Fading Benefit (Preventative) (Mid +9.1%, Late +4.2%)
NFP	200	30.00	2.439	~171 mg	Female: Neutral (Mid -0.9%, Late -2.2%) Male: Hidden Hazard (Late Toxicity) (Mid +3.2%, Late -2.0%)
Nicotinamide Riboside (NR)	1000	150.00	12.195	~854 mg	Female: Senescence Rescue (Late Only) (Mid -2.1%, Late +3.0%) Male: Detrimental / Risk (Mid -2.8%, Late +0.4%)
Oxaloacetate (OAA)	2200	330.00	26.829	~1,878 mg	Female: Minor/Neutral (Mid +2.7%, Late +3.2%) Male: Fading Benefit (Preventative) (Mid +4.2%, Late +3.1%)
PB125	Diet	-	-	-	Female: Minor/Neutral (Mid +1.2%, Late +3.2%) Male: Detrimental / Risk (Mid -4.2%, Late +2.3%)
Protandim (Prot)	600	90.00	7.317	~512 mg	Female: Minor/Neutral (Mid +1.5%, Late +2.8%) Male: Fading Benefit (Preventative) (Mid +8.7%, Late +4.0%)
Rapamycin (Rapa)	42	6.30	0.512	~36 mg	Female: Fading Benefit (Preventative) (Mid +20.9%, Late +16.0%) Male: Fading Benefit (Preventative) (Mid +16.8%, Late +8.6%)
Rapamycin (Rapa)	4.7	0.70	0.057	~4 mg	Female: Fading Benefit (Preventative) (Mid +16.4%, Late +13.6%) Male: Consistent / Senescence Rescue (Mid +3.3%, Late +6.2%)
Rapamycin (Rapa)	14	2.10	0.171	~12 mg	Female: Fading Benefit (Preventative) (Mid +17.7%, Late +16.3%) Male: Fading Benefit (Preventative) (Mid +13.4%, Late +9.5%)
Rapa_ACA	14.7, 1000	-	-	Stack	Female: Fading Benefit (Preventative) (Mid +20.4%, Late +18.3%) Male: Fading Benefit (Preventative) (Mid +22.4%, Late +19.7%)
Rapa_hi_cycle	42	6.30	0.512	~36 mg	Female: Consistent / Senescence Rescue (Mid +8.0%, Late +9.9%) Male: Fading Benefit (Preventative) (Mid +9.3%, Late +8.4%)
Rapa_hi_start_stop	42	6.30	0.512	~36 mg	Female: Fading Benefit (Preventative) (Mid +4.0%, Late +3.7%) Male: Fading Benefit (Preventative) (Mid +10.7%, Late +4.3%)
Resveratrol (Res)	1200	180.00	14.634	~1,024 mg	Female: Minor/Neutral (Mid +1.6%, Late +2.3%) Male: Minor/Neutral (Mid +6.0%, Late +1.5%)
Resveratrol (Res)	300	45.00	3.659	~256 mg	Female: Minor/Neutral (Mid +3.2%, Late +0.9%) Male: Minor/Neutral (Mid +1.5%, Late -1.8%)
Simvastatin (Sim)	12	1.80	0.146	~10 mg	Female: Minor/Neutral (Mid +2.8%, Late +0.6%) Male: Minor/Neutral (Mid +2.9%, Late +1.9%)
Simvastatin (Sim)	120	18.00	1.463	~102 mg	Female: Minor/Neutral (Mid +0.9%, Late +2.7%) Male: Detrimental / Risk (Mid -4.9%, Late +2.5%)
Sulforaphane (Sul)	5	0.75	0.061	~4 mg	Female: Neutral (Mid -1.7%, Late +2.0%) Male: Detrimental / Risk (Mid -4.6%, Late +0.8%)
Syringaresinol (Syr)	300	45.00	3.659	~256 mg	Female: Neutral (Mid -1.7%, Late -0.8%) Male: Hidden Hazard (Late Toxicity) (Mid +4.1%, Late -1.7%)
TM5441 (PAI-1)	60	9.00	0.732	~51 mg	Female: Neutral (Mid -0.3%, Late -0.5%) Male: Detrimental / Risk (Mid -5.0%, Late +1.5%)
Ursolic Acid (UA)	2000	300.00	24.390	~1,707 mg	Female: Neutral (Mid -0.4%, Late -1.2%) Male: Minor/Neutral (Mid +6.2%, Late +0.5%)
Ursodeoxycholic Acid (UDCA)	5000	750.00	60.976	~4,268 mg	Female: Minor/Neutral (Mid +1.1%, Late +1.5%) Male: Minor/Neutral (Mid +6.9%, Late +0.1%)
beta-GPA (bGPA)	3300	495.00	40.244	~2,817 mg	Female: Neutral (Mid -0.9%, Late +1.7%) Male: Minor/Neutral (Mid +0.1%, Late +2.3%)

[DocFLWI]

This is great information to help in refining our stacks. At age 68, I see what I can begin to eliminate, and where to place emphasis.

[ORRAPA]

I’m more interested n the age cutoffs. It looks like I may need to drop sulfurophane based on this data.

[ORRAPA]

Just pointing out the obvious that Rapa appears to need a higher dosage than current regimens to have effectiveness in a males. This could explain why human studies have been inconclusive to date.

Oh wow just realized those are daily, not weekly dosages. We’re going to need that GSK molecule with the enhanced motor effect to have useful results in humans without immunosuppression.

[Kelman]

Thanks @RapAdmin . This is great info and easy to read, even for a simpleminded guy like me!

[RapAdmin]

@ORRAPA

Just pointing out the obvious that Rapa appears to need a higher dosage than current regimens to have effectiveness in a males. This could explain why human studies have been inconclusive to date.

We’ve discussed this in the past (and Matt Kaeberlein and others have commented on this in some of his videos), this is a case where the mouse data does not align with the human data. We don’t see the large difference in responsiveness (blood levels) of females compared to males, in the human use situations.

In mice, the blood levels are much higher in female mice than male mice (for the same dose). This is not the case in humans.

For example, because of this, there is no difference in dosing regimens between human males and females in organ transplant patients.

Just confirming this via Google Gemini:

Prompt:

Is sirolimus (rapamycin) dosed differently for men and women in transplant treatment patients?

Gemini Response:

No, sirolimus (rapamycin) is not dosed differently for men and women in terms of standard starting guidelines for transplant patients.

The initial dose is typically determined by the type of transplant, the patient’s weight (specifically for those under 40 kg), and their immunologic risk level—not their biological sex.

While the starting dose is the same, the way the drug affects men and women can differ. Here is a breakdown of why the dose is the same and the gender-specific nuances you should be aware of.

1. Why the Starting Dose is the Same

Sirolimus has a “narrow therapeutic index,” meaning the difference between a helpful dose and a toxic one is small. Because every individual metabolizes the drug differently (regardless of gender), doctors rely on Therapeutic Drug Monitoring (TDM) rather than gender-based charts.

• Protocol: Everyone starts on a standard fixed dose (often a loading dose followed by a maintenance dose, such as 2 mg/day).
• Adjustment: Doctors measure the “trough” levels of the drug in the blood (usually 5–7 days after starting).
• Result: If a female patient clears the drug faster or slower than a male patient due to metabolic differences, this will show up in the blood test, and the doctor will adjust the dose accordingly to keep it in the target range (usually 5–15 ng/mL, depending on the protocol).

2. Biological Differences (Pharmacokinetics)

Although the guidelines don’t separate men and women, research has shown some subtle biological differences, though they are usually not significant enough to change standard practice:

• Clearance Rates: Some studies suggest slight variations in how quickly men and women clear the drug from their systems, often related to body surface area or liver metabolism (CYP3A5 enzymes).
• Impact: These differences are automatically corrected for during the blood monitoring phase.

3. Gender-Specific Side Effects (In High-Dose Rapamycin Transplant Patients)

While the dose doesn’t change based on gender, the side effects can be distinct for men and women. This may influence a doctor’s decision to use this drug or how they monitor the patient.

Feature	Men	Women
Hormonal Impact	Can lower testosterone levels.	Can cause menstrual irregularities (amenorrhea or heavy bleeding).
Reproductive Health	May reduce sperm count (oligospermia/azoospermia), which is usually reversible if the drug is stopped.	Associated with the formation of ovarian cysts.
Fertility	Potential issues with fertility; counseling is often recommended before starting.	Potential issues with fertility; counseling is often recommended before starting.

Summary of Factors That Do Change Dosing

If you are looking for what does officially change the dose, it is usually one of the following:

• Weight: Patients under 40 kg (88 lbs) typically receive a dose adjusted to their body surface area (1 mg/m²).
• Liver Function: Patients with hepatic impairment (liver damage) generally require a reduced maintenance dose (reduced by approximately 33% to 50%).
• Drug Interactions: Medications like cyclosporine, diltiazem, or ketoconazole can drastically change sirolimus levels, requiring major dose adjustments.